Skip to:
For many years, Polycystic Ovary Syndrome has been one of the most commonly misunderstood conditions in women’s health. Despite affecting an estimated 1 in 10 women worldwide, the name itself often caused confusion, delayed diagnosis, and left many patients feeling unheard.
Now, after a major international collaboration involving researchers, clinicians, and patient advocacy groups, PCOS has officially been renamed Polyendocrine Metabolic Ovarian Syndrome. The change was announced in 2026 following publication in The Lancet and presentations at the European Congress of Endocrinology.
While the new terminology may take some getting used to, the goal is simple: to better reflect what this condition actually is – a complex hormonal and metabolic condition that affects far more than the ovaries alone.
Importantly, if you already have a diagnosis of PCOS, this name change does not mean your symptoms were “wrong” before, nor does it suddenly change your fertility journey. Instead, it represents a broader shift in women’s healthcare toward more accurate language, improved understanding, and greater investment in research and support for you.
Previous name polycystic ovary syndrome has long been criticised by both clinicians and patients because it did not accurately describe the condition.
Many people diagnosed with PCOS do not actually have ovarian cysts. Instead, the ovaries may contain multiple small follicles, which are immature egg sacs rather than true cysts. At the same time, many people without PCOS can also have polycystic-appearing ovaries on ultrasound.
Experts increasingly recognised that the name placed too much emphasis on the ovaries and fertility, while overlooking the broader hormonal and metabolic impacts of the condition.
New name Polyendocrine Metabolic Ovarian Syndrome was chosen to better reflect that PMOS can involve:
Researchers involved in the international consensus process stated that the change aims to improve awareness, reduce stigma, support earlier diagnosis, and encourage more holistic care.
At this stage, the diagnostic criteria themselves have not significantly changed.
Most clinicians still use the internationally recognised Rotterdam Criteria, which diagnose the condition when two out of the following three features are present:
In other words, if you previously met the criteria for PCOS, you would still meet the criteria for PMOS.
However, what is changing is the way healthcare professionals understand and discuss the condition.
The shift to PMOS acknowledges the broader health implications of the condition. Rather than focusing solely on ovarian and reproductive features, clinicians are increasingly recognising its potential impact on:
This broader perspective is important because many patients have historically experienced delayed diagnosis or fragmented care, particularly if fertility was not their immediate concern.
For most patients, the practical aspects of treatment will remain largely the same.
Management of PMOS is still highly individualised and depends on your symptoms, goals, stage of life, and overall health. Treatment may include:
What the name change does encourage is a more comprehensive approach to care.
Rather than focusing solely on whether someone is trying to conceive, PMOS highlights the importance of supporting long-term hormonal, metabolic, reproductive, and emotional wellbeing together.
For fertility patients, these advances have the potential to improve outcomes across the entire care journey. This may include earlier diagnosis of underlying conditions, more coordinated multidisciplinary care, enhanced pregnancy management, and greater awareness among GPs and other healthcare professionals. Over time, it may also support the development of more personalised treatment strategies while driving further research into fertility outcomes and long-term health.
The renaming of PCOS to PMOS represents something much bigger than terminology alone.
Historically, many gynaecological and reproductive health conditions have been underfunded, under-researched, and misunderstood. Patients with symptoms such as irregular periods, pelvic pain, weight changes, or infertility have often faced delays in diagnosis. They have commonly felt blame for their symptoms or had their concerns minimised.
The global move toward PMOS reflects growing recognition that women’s health deserves:
The fact that this change followed more than a decade of international collaboration between clinicians, researchers, and patients is significant. It demonstrates that women’s lived experiences are increasingly being heard and incorporated into medical care.
Encouragingly, experts believe the transition to PMOS will help strengthen understanding and support for reproductive and hormonal health. The change is expected to contribute to greater public awareness, increased investment in research and healthcare funding, improved medical education, and reduced stigma surrounding reproductive conditions.
It may also encourage the development of more holistic models of care that better address the broader health needs of women. The updated terminology will be introduced gradually across the international medical community, with full incorporation into future clinical guidelines expected by 2028.
Although the name has changed from PCOS to PMOS, the experiences of those living with the condition remain very real and very valid.
For many patients, the new name may feel like an important acknowledgment that this condition is more complex than simply “ovarian cysts.” It reflects a growing understanding that hormonal, metabolic, reproductive, and emotional health are deeply connected.
Most importantly, this shift signals positive momentum in women’s healthcare. As awareness grows and research expands, there is hope for earlier diagnosis, more compassionate care, and better long-term outcomes for the millions of women living with PMOS worldwide.
